ArticleDiabetes, obesity & metabolism2026
Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population-Based Study.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population-Based Study.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsThis study aimed to analyse incident glucose lowering drug (GLD) utilisation in Australia between the period 2014 and 2024. MATERIALS AND
methodsAustralian Pharmaceutical Benefits Scheme (PBS) data (10% PBS dataset) were analysed to assess the proportions of incident monotherapy, dual therapy and triple therapy and the proportion of prescriptions dispensed for each GLD class. Annual changes in age at incident GLD initiation were also quantified.
results49 129 individuals were included. The proportion of individuals prescribed incident GLD as monotherapy decreased from 90.4% in 2014 to 77.2% in 2024, while incident dual therapy rose from 9.3% to 21.8% and incident triple therapy from 0.2% to 1.0%. The overall proportion of incident metformin therapy (monotherapy or in combination with other GLDs) decreased from 83.9% in 2014 to 40.1% in 2024, with incident metformin as monotherapy falling from 82.7% to 29.1% over the same period. Proportions of incident SGLT2i and GLP-1 RA (monotherapy or in combination with other GLDs) were 35.7% and 11.2%, respectively, in 2024. Over the study period, age at the time of incident prescribing increased for all GLD classes, except GLP-1 RA, which decreased.
conclusionsOver the past decade, substantial changes in incident GLD prescribing have occurred in Australia. While metformin continues to play a central role as initial treatment, major shifts toward use of initial dual therapy, including SGLT2i and GLP-1RA, have occurred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.